| Title |
Treatment-related mortality with aflibercept in cancer patients: a meta-analysis
|
|---|---|
| Published in |
European Journal of Clinical Pharmacology, January 2014
|
| DOI | 10.1007/s00228-013-1633-2 |
| Pubmed ID | |
| Authors |
Wei-Xiang Qi, Li-Na Tang, Zan Shen, Yang Yao |
| Abstract |
Aflibercept, a fully humanized vascular endothelial growth factor (VEGF)-targeted agent, has emerged as an effective therapy in the treatment of various solid tumors. We carried out an up-to-date meta-analysis to determine the risk of fatal adverse events (FAEs) in cancer patients treated with aflibercept. |
X Demographics
The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Spain | 2 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 50% |
| Practitioners (doctors, other healthcare professionals) | 1 | 50% |
Mendeley readers
The data shown below were compiled from readership statistics for 14 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 14 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 3 | 21% |
| Lecturer | 2 | 14% |
| Student > Bachelor | 2 | 14% |
| Student > Master | 2 | 14% |
| Student > Doctoral Student | 1 | 7% |
| Other | 2 | 14% |
| Unknown | 2 | 14% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 7 | 50% |
| Agricultural and Biological Sciences | 1 | 7% |
| Pharmacology, Toxicology and Pharmaceutical Science | 1 | 7% |
| Sports and Recreations | 1 | 7% |
| Psychology | 1 | 7% |
| Other | 0 | 0% |
| Unknown | 3 | 21% |
Attention Score in Context
This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 04 April 2014.
All research outputs
#15,705,005
of 24,133,587 outputs
Outputs from European Journal of Clinical Pharmacology
#2,065
of 2,658 outputs
Outputs of similar age
#188,707
of 313,950 outputs
Outputs of similar age from European Journal of Clinical Pharmacology
#25
of 34 outputs
Altmetric has tracked 24,133,587 research outputs across all sources so far. This one is in the 34th percentile – i.e., 34% of other outputs scored the same or lower than it.
So far Altmetric has tracked 2,658 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.2. This one is in the 21st percentile – i.e., 21% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 313,950 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 39th percentile – i.e., 39% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 34 others from the same source and published within six weeks on either side of this one. This one is in the 29th percentile – i.e., 29% of its contemporaries scored the same or lower than it.